NCT00001596View on ClinicalTrials.gov

Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

May 9, 2016

Conditions
AlbinismInborn Errors of MetabolismOculocutaneous AlbinismPlatelet Storage Pool DeficiencyPulmonary Fibrosis
Interventions
DRUG

Pirfenidone

Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.

DRUG

Placebo

Placebo (3 pills), three times daily.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Human Genome Research Institute (NHGRI)

NIH

lead

William Gahl, M.D.

NIH

NCT00001596 - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome | Biotech Hunter | Biotech Hunter